From: The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer
 |  | n= 102 | % |
---|---|---|---|
Tumor | |||
 | T1 | 66 | 64.7 |
 | T2 | 27 | 26.5 |
 | T3 | 6 | 5.9 |
 | T4 | 3 | 2.9 |
Nodus | |||
 | Negative | 58 | 56.9 |
 | Positive | 42 | 41.2 |
 | Unknown | 2 | 1.9 |
Grade | Â | Â | Â |
 | I | 30 | 29.4 |
 | II | 35 | 34.3 |
 | III | 37 | 36.3 |
Estrogen receptor (ER) | |||
 | Negative | 24 | 23.5 |
 | Positive | 78 | 76.5 |
Progesterone receptor (PR) | |||
 | Negative | 35 | 34.3 |
 | Positive | 67 | 65.7 |
HER2 | |||
 | Negative | 84 | 82.4 |
 | Positive | 18 | 17.6 |
Ki67 | |||
 | Negative | 21 | 20.6 |
 | + | 37 | 36.3 |
 | ++ | 20 | 19.6 |
 | +++ | 24 | 23.5 |
Adjuvant treatment | |||
 | Chemotherapy | 35 | 34.3 |
 | Hormonal | 44 | 43.1 |
 |    Tamoxifen | 23 | 22.5 |
 |    Aromatase |  |  |
 |    inhibitor | 17 | 16.7 |
 |    Both | 2 | 2.0 |
 |    Unknown | 2 | 2.0 |
 | Radiotherapy | 74 | 72.5 |
 | Trastuzumab | 3 | 2.9 |